AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7990854
Drug: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol)
RxNorm normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) at a mean dose of 37 +/- 10 mg intramuscularly
Trial: 7990854
Drug: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol)
RxNorm normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) co-administered with a mildly dyskinetic dose of levodopa infused intravenously
Trial: 7990854
Drug: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol)
RxNorm normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) at low doses (2.5 and 5 mg)
Trial: 31958428
Drug: Adherent to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherent to bisphosphonate therapy
Trial: 31958428
Drug: Underwent DXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Underwent DXA testing prior to bisphosphonate prescription and incident fracture
Trial: 24283172
Drug: Estradiol hemihydrate
RxNorm normalized name: Estradiol hemihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol hemihydrate 2 mg
Trial: 24283172
Drug: No menopausal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No menopausal therapy (Control)
Trial: 12814333
Drug: Oral clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clodronate 1600 mg/day
Trial: 15877555
Drug: Nonpharmacological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonpharmacological intervention (5 consecutive days and nights of efforts to decrease daytime in-bed time, 30 minutes or more of daily sunlight exposure, increased physical activity, structured bedtime routine, and efforts to decrease nighttime noise and light)
Trial: 10328256
Drug: Vigabatrin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (50 to 60 mg/kg per day)
Trial: 10328256
Drug: Carbamazepine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (15 to 20 mg/kg per day)
Trial: 2022014
Drug: Aspirin 324
RxNorm normalized name: aspirin 324 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 324 mg daily
Trial: 25496464
Drug: Tofacitinib 1
RxNorm normalized name: tofacitinib 11 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 1 mg BID
Trial: 25496464
Drug: Tofacitinib 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 3 mg BID
Trial: 17322494
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 60 microg/kg daily
Trial: 17322494
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) (15, 30 microg/kg daily)
Trial: 11245709
Drug: Baclofen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (20 mg three times daily)
Trial: 9716583
Drug: G‐CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (5 microgram/kg/d) subcutaneously
Trial: 26503137
Drug: Oral liquid
RxNorm normalized name: ACAI ORAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid nutrition supplement (ONS) intervention
Trial: 19917874
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Hydrochlorothiazide and Atenolol)
Trial: 12039398
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) therapy, 40-60 sessions of oxygen breathing at 2.5-bar increased pressure in a hyperbaric chamber
Trial: 10607254
Drug: High-dose, short-duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose, short-duration interferon-alpha2b (10 million units for 14 weeks)
Trial: 10607254
Drug: Standard interferon
RxNorm normalized name: INTERFERON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard interferon regimen (3 MU three times weekly for 6 months)
Trial: 10607254
Drug: High-dose, short-duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose, short-duration interferon-alpha2b
Trial: 8607618
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + TAM therapy (Arm A)
Trial: 8607618
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + MPA therapy (Arm B)
Trial: 2182234
Drug: Intravenous anistreplase
RxNorm normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anistreplase (APSAC)
Trial: 6280836
Drug: No BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No BCG immunotherapy
Trial: 30545701
Drug: Labetalol (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (0.3 mg·kg‐1 i.v.)
Trial: 25682576
Drug: Ruxolitinib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (15 or 20 mg twice a day)
Trial: 21791454
Drug: hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hylan G-F 20 (Synvisc)
Trial: 9415336
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg ondansetron suppository once a day
Trial: 9415336
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg intravenous ondansetron on day 1 followed by 8 mg tablet twice daily on days 2 and 3 (i.v. + p.o. group)
Trial: 8424510
Drug: Alkalinized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkalinized lidocaine (20 mL of 1.37% lidocaine plus 1 mL sodium bicarbonate per 10 mL 1.5% lidocaine)
Trial: 8424510
Drug: Non-alkalinized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-alkalinized lidocaine (20 mL of 1.37% lidocaine with added 1:200,000 epinephrine)
Trial: 3310622
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of testosterone enanthate
Trial: 27281019
Drug: Pegylated interferon‐alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon‐alfa‐2a (Peg‐IFN‐α) therapy
Trial: 27281019
Drug: Nucleos(t)ide analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleos(t)ide analog alone or in combination with Peg‐IFN‐α
Trial: 12224570
Drug: Chloroquine combined
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine combined with primaquine (25 mg/kg in 3 doses over 48 hours + 30 mg primaquine daily for 28 days)
Trial: 9833916
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion (250 microg/h after a 250‐microg bolus for 5 days)
Trial: 7855216
Drug: Flunitrazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (1 mg) administered daily for 8 days
Trial: 7855216
Drug: Flunitrazepam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (single dose)
Trial: 24379592
Drug: Somatostatin and
RxNorm normalized name: Somatostatin and analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin and dexamethasone treatment
Trial: 24379592
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition and nasogastric (NG) tube feeding (Control)
Trial: 21757237
Drug: Standardized stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized stepwise treatment regimen (SSTR)
Trial: 16883525
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium group (1000 mg element calcium and 400 units of vitamin D daily for 12 months)
Trial: 16883525
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium group (300 mg element calcium and 300 units of vitamin D daily for 12 months)
Trial: 27466236
Drug: High-dose ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ibuprofen (2400 mg/day for 4 or 12 weeks)
Trial: 23819220
Drug: Routine EA
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine EA treatment
Trial: 12798752
Drug: Hepatic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic artery occlusion (HAO) followed by intraportal 5‐fluorouracil (5‐Fu) infusion (1000 mg/m(2) for 5 days every sixth week)
Trial: 12798752
Drug: Intra-arterial 5‐Fu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial 5‐Fu infusion + Leucovorin (100 mg i.v. for 2 days every second week) (HAI)
Trial: 3928215
Drug: tocainide hydrochloride
RxNorm normalized name: Tocainide Hydrochloride
DrugBank: Tocainide (DB01056)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tocainide hydrochloride (200-600 mg daily)
Trial: 11736967
Drug: Patient-controlled postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled postoperative oral feeding (PC group)
Trial: 11736967
Drug: Fixed regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed regimen postoperative oral feeding (FR group)
Trial: 9237935
Drug: GLA supplementation
RxNorm normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLA supplementation at doses of 3.0 g/d and 6.0 g/d
Trial: 9237935
Drug: GLA supplementation
RxNorm normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLA supplementation at doses of 3.0 g/d
Trial: 2964992
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose HRP112 (25mg DMPA plus 5mg estradiol cypionate)
Trial: 2964992
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose HRP112 (12.5mg DMPA plus 2.5mg estradiol cypionate)
Trial: 2964992
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose DMPA (25mg)
Trial: 2964992
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose DMPA (12.5mg)
Trial: 2964992
Drug: Estrogen-progestogen combination
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-progestogen combination preparations
Trial: 19245538
Drug: Poly-l-lactic acid
RxNorm normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-l-lactic acid (PLA) injections administered every 2 weeks from week 0 (immediate group)
Trial: 19245538
Drug: Poly-l-lactic acid
RxNorm normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-l-lactic acid (PLA) injections administered every 2 weeks from week 24 (deferred group)
Trial: 11501509
Drug: Calcitriol 3
RxNorm normalized name: CALCITRIOL 3MCG/GM OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 3 microg g(‐1) ointment applied twice daily
Trial: 11501509
Drug: Calcitriol combined
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol combined with betamethasone valerate (each applied separately, once daily)
Trial: 11501509
Drug: Calcitriol 3
RxNorm normalized name: CALCITRIOL 3MCG/GM OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 3 microg g(‐1) ointment
Trial: 9532517
Drug: Irbesartan 75
RxNorm normalized name: irbesartan 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 75 mg once a day
Trial: 9532517
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg once a day
Trial: 9532517
Drug: Irbesartan 75
RxNorm normalized name: irbesartan 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 75 mg twice a day
Trial: 8300487
Drug: Aerosolised nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolised nifedipine 5 mg
Trial: 8300487
Drug: Aerosolised verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolised verapamil 5 mg
Trial: 31870942
Drug: Cortisol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (1 mg intravenously)
Trial: 30200398
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of dark chocolate containing 70% cocoa
Trial: 30200398
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of milk chocolate
Trial: 15979994
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg Triptorelin (GnRH agonist)
Trial: 9688055
Drug: Moderately stressed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately stressed capsules
Trial: 9688055
Drug: Unstressed capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unstressed capsules
Trial: 3176071
Drug: Ethanol (95%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (95%, 0.84 ml/kg) as positive control
Trial: 30184254
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% (2.5 ml)
Trial: 30184254
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% (5.0 ml)
Trial: 30184254
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% (10 ml)
Trial: 30184254
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% (15 ml)
Trial: 30184254
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% (20 ml)
Trial: 26032281
Drug: Yohimbine (α2-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (α2-adrenoceptor antagonist)
Trial: 24385236
Drug: ETC-1002 80
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 80 mg QD for 2 weeks followed by 120 mg QD for 2 weeks
Trial: 18824288
Drug: Ferumoxytol (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol (IV injection of 17 mL over 17 seconds)
Trial: 18824288
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo (IV injection of 17 mL over 17 seconds)
Trial: 12359651
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (100 micro g, twice daily)
Trial: 1467074
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg i.m. 12-hourly for 2 days
Trial: 6584028
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg prostaglandin E2 vaginal pessaries
Trial: 29508715
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of montelukast for 2 weeks followed by 10 mg of montelukast for 2 weeks
Trial: 29508715
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of prednisolone for 2 weeks followed by 10 mg of montelukast for 2 weeks
Trial: 29508715
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of montelukast for 2 weeks
Trial: 19514864
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg/hydrochlorothiazide 12.5 mg
Trial: 23235355
Drug: Moxonidine 0.4
RxNorm normalized name: moxonidine 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.4 mg
Trial: 17510755
Drug: Asmasal inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asmasal inhaler (micronized drug)
Trial: 8996294
Drug: Titrated oral
RxNorm normalized name: magnesium citrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oral ramipril (n = 20)
Trial: 8996294
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (control, n = 15)
Trial: 8488685
Drug: Theospirex retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theospirex retard 300 mg (single evening dose)
Trial: 8488685
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (400 mg, single evening dose)
Trial: 8488685
Drug: Both preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preparations (Theospirex retard and reference preparation)
Trial: 19301059
Drug: Pantoprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (80 mg i.v. bolus followed by 8 mg/h for 1 h)
Trial: 15578473
Drug: target-controlled propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: target-controlled propofol (1-8 microg/mL plasma target concentration)
Trial: 11382369
Drug: Propionyl-L-carnitine (2g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (2g/day orally) for 6 months
Trial: 24531357
Drug: Semitendinosus +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semitendinosus + gracilis (ST/G)
Trial: 23725526
Drug: 7.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g/day of dietary fiber for 12 weeks
Trial: 19692210
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg i.v. once daily
Trial: 19692210
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g i.v. once daily plus Metronidazole 500 mg i.v. twice daily
Trial: 15600227
Drug: Combined (Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined (Medication + CBT for 10 weeks)
Trial: 15600227
Drug: Overlapping (Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overlapping (Medication for 5 weeks, CBT introduced at week 4, medication withdrawal after 5 weeks)
Trial: 15600227
Drug: Medication ->
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication -> CBT (Medication alone for 5 weeks, then CBT alone for 5 weeks)
Trial: 8215749
Drug: Nizatidine, 150
RxNorm normalized name: Nizatidine, 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine, 150 mg twice daily
Trial: 8398824
Drug: Melphalan treatment
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan treatment
Trial: 28954640
Drug: beta2-1 fructan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta2-1 fructan (3x5 g/d for 28 days)
Trial: 28954640
Drug: maltodextrin (3x5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maltodextrin (3x5 g/d for 28 days)
Trial: 21694627
Drug: Tianeptine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (75 mg)
Trial: 16931978
Drug: Endobronchial blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial blocker
Trial: 1290169
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III (ATIII) replacement therapy before the induction of anaesthesia and throughout surgery
Trial: 1290169
Drug: No Antithrombin
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Antithrombin III replacement therapy
Trial: 30673543
Drug: Levodopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (100 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks
Trial: 30673543
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks
Trial: 30673543
Drug: Levodopa in
RxNorm normalized name: levodopa Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa in combination with carbidopa
Trial: 29494727
Drug: Ranibizumab and
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab and laser combination therapy
Trial: 21415158
Drug: Copeptin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin levels in the highest quartile (>122 pmol/L)